Your browser doesn't support javascript.
loading
Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction.
Allen, Julie K; Armaiz-Pena, Guillermo N; Nagaraja, Archana S; Sadaoui, Nouara C; Ortiz, Tatiana; Dood, Robert; Ozcan, Merve; Herder, Danielle M; Haemmerle, Monika; Gharpure, Kshipra M; Rupaimoole, Rajesha; Previs, Rebecca A; Wu, Sherry Y; Pradeep, Sunila; Xu, Xiaoyun; Han, Hee Dong; Zand, Behrouz; Dalton, Heather J; Taylor, Morgan; Hu, Wei; Bottsford-Miller, Justin; Moreno-Smith, Myrthala; Kang, Yu; Mangala, Lingegowda S; Rodriguez-Aguayo, Cristian; Sehgal, Vasudha; Spaeth, Erika L; Ram, Prahlad T; Wong, Stephen T C; Marini, Frank C; Lopez-Berestein, Gabriel; Cole, Steve W; Lutgendorf, Susan K; De Biasi, Mariella; Sood, Anil K.
Afiliação
  • Allen JK; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Armaiz-Pena GN; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Nagaraja AS; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Sadaoui NC; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Ortiz T; Division of Cancer Biology, Ponce Research Institute, Ponce, Puerto Rico.
  • Dood R; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Ozcan M; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Herder DM; Department of Basic Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
  • Haemmerle M; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Gharpure KM; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Rupaimoole R; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Previs RA; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Wu SY; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Pradeep S; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Xu X; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Han HD; Systems Medicine and Bioengineering Department, Houston Methodist Research Institute, Weill Cornell Medical College, Houston, Texas.
  • Zand B; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Dalton HJ; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Taylor M; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Hu W; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Bottsford-Miller J; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Moreno-Smith M; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Kang Y; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Mangala LS; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Rodriguez-Aguayo C; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Sehgal V; Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Spaeth EL; Department of System Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Ram PT; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Wong STC; Department of System Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Marini FC; Systems Medicine and Bioengineering Department, Houston Methodist Research Institute, Weill Cornell Medical College, Houston, Texas.
  • Lopez-Berestein G; Department of Pathology, Genomic Medicine and Radiology, Houston Methodist Hospital, Weill Cornell Medical College, Houston, Texas.
  • Cole SW; Institute for Regenerative Medicine, Wake Forest University, Winston-Salem, North Carolina.
  • Lutgendorf SK; Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • De Biasi M; Center for RNA Interference and Non-coding RNA, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Sood AK; Department of Medicine, Division of Oncology Hematology-Oncology, University of California, Los Angeles, California.
Cancer Res ; 78(12): 3233-3242, 2018 06 15.
Article em En | MEDLINE | ID: mdl-29661830
Mounting clinical and preclinical evidence supports a key role for sustained adrenergic signaling in the tumor microenvironment as a driver of tumor growth and progression. However, the mechanisms by which adrenergic neurotransmitters are delivered to the tumor microenvironment are not well understood. Here we present evidence for a feed-forward loop whereby adrenergic signaling leads to increased tumoral innervation. In response to catecholamines, tumor cells produced brain-derived neurotrophic factor (BDNF) in an ADRB3/cAMP/Epac/JNK-dependent manner. Elevated BDNF levels in the tumor microenvironment increased innervation by signaling through host neurotrophic receptor tyrosine kinase 2 receptors. In patients with cancer, high tumor nerve counts were significantly associated with increased BDNF and norepinephrine levels and decreased overall survival. Collectively, these data describe a novel pathway for tumor innervation, with resultant biological and clinical implications.Significance: Sustained adrenergic signaling promotes tumor growth and metastasis through BDNF-mediated tumoral innervation. Cancer Res; 78(12); 3233-42. ©2018 AACR.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Norepinefrina / Fator Neurotrófico Derivado do Encéfalo / Receptores Adrenérgicos beta 3 / Retroalimentação Fisiológica / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Norepinefrina / Fator Neurotrófico Derivado do Encéfalo / Receptores Adrenérgicos beta 3 / Retroalimentação Fisiológica / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2018 Tipo de documento: Article